Tissue Stem Cell-Based Therapies in Parkinson’s Disease: A Scoping Review of Therapeutic Mechanisms and Translational Outcomes

• Published in: Cells (Basel, Switzerland) Vol. 14; no. 11; p. 822
• Main Authors: Cueva, Emily, Wiesheu, Andrea, Sordo, Zaira, González, Jailene, Falconi, Sabine, Rodas, Jose A., Leon-Rojas, Jose E.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2025; MDPI
• Subjects: Animal cognition; Animal models; Animals; Apoptosis; Cell therapy; Cell- and Tissue-Based Therapy - methods; Cognitive ability; Development and progression; Disease; Diseases; Dopamine receptors; Dopaminergic Neurons; Enzymes; Health aspects; Humans; Microbiota; Movement disorders; Neural stem cells; Neurodegenerative diseases; neuroinflammation; Neurons; neuroregeneration; Parkinson Disease - therapy; Parkinson's disease; Stem Cell Transplantation - methods; Stem cells; Stem Cells - cytology; Synuclein; Systematic Review; tissue stem cell therapy; Translation; Translational Research, Biomedical; Transplantation; Transplants; Treatment Outcome; tissue stem cell therapy; neuroinflammation; neuroregeneration; Parkinson’s disease; dopaminergic neurons
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells14110822

(1) Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by dopaminergic neuronal loss. Tissue stem cell-based therapies have emerged as promising candidates for disease modification and symptomatic relief. This scoping review aims to systematically synthesise the literature on tissue stem cell therapies for PD across cellular, animal, and human studies, with a focus on transplantation strategies, mechanisms of action, and therapeutic outcomes. (2) Methods: We identified 1017 records by querying PubMed, Scopus, Cochrane, and the Virtual Health Library. After screening and applying eligibility criteria, 33 experimental studies were included. Data were extracted on study design, tissue stem cell source, type of subject, and therapeutic effects. (3) Results: Most studies (n = 25) involved animal models, with a minority (n = 8) focusing on human applications. Tissue stem cell therapies showed potential to promote dopaminergic differentiation, reduce inflammation and apoptosis, and improve behavioural and motor outcomes. Autologous transplants yielded a higher safety and efficacy compared to allogeneic ones. The beneficial mechanisms of tissue stem cells included neurotrophic support, mitochondrial protection, modulation of the gut–brain axis, and α-synuclein clearance. (4) Conclusions: Tissue stem cell therapies represent a promising approach for PD. However, standardised protocols and long-term safety assessments are essential to optimise their translational potential.